Diabetes Spectrum最新文献_第5页

A Qualitative Study of Barriers to Medication-Taking Among People With Type 2 Diabetes Using the Theoretical Domains Framework. 利用理论领域框架对 2 型糖尿病患者服药障碍的定性研究。

Diabetes Spectrum Pub Date : 2024-03-05 eCollection Date: 2024-01-01 DOI: 10.2337/ds23-0038

Michael Vallis, Susie Jin, Agnieszka Klimek-Abercrombie, Ginnie Ng, Noah M Ivers

{"title":"A Qualitative Study of Barriers to Medication-Taking Among People With Type 2 Diabetes Using the Theoretical Domains Framework.","authors":"Michael Vallis, Susie Jin, Agnieszka Klimek-Abercrombie, Ginnie Ng, Noah M Ivers","doi":"10.2337/ds23-0038","DOIUrl":"10.2337/ds23-0038","url":null,"abstract":"Objective: We aimed to better understand the challenges related to type 2 diabetes medication-taking through Theoretical Domains Framework (TDF)-guided interviews with people with type 2 diabetes with varying degrees of medication-taking.Methods: One-on-one qualitative interviews following a semistructured discussion guide informed by the TDF were conducted. Thirty people with type 2 diabetes in Canada were interviewed, with representation from across the country, of both sexes (47% female), of people with various diabetes durations (mean 12.9 ± 7.9 years), with different types of medication plans (n = 15 on polypharmacy), and with various medication-taking levels (n = 10 each for low-, medium-, and high-engagement groups).Results: Themes related to medication-taking from interviews mapped to 12 of the 14 TDF theme domains, with the exclusion of the knowledge and skills domains. The most prominent domains, as determined by high-frequency themes or themes for which people with low and high medication-taking had contrasting perspectives, were 1) emotion; 2) memory, attention, and decision processes; 3) behavioral regulation; 4) beliefs about consequences; 5) goals; and 6) environmental context and resources.Conclusion: Through our interviews, several areas of focus emerged that may help efforts to increase medication-taking. To validate these findings, future quantitative research is warranted to help support people with type 2 diabetes in overcoming psychological and behavioral barriers to medication-taking.","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"37 3","pages":"264-272"},"PeriodicalIF":0.0,"publicationDate":"2024-03-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://www.ncbi.nlm.nih.gov/pmc/articles/PMC11327164/pdf/","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"142000986","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Optimizing Diabetes Care Through Listening To Multiple Voices 倾听多方声音，优化糖尿病护理

Diabetes Spectrum Pub Date : 2024-02-22 DOI: 10.2337/ds24-0015

A. E. Caballero

引用次数: 0

Grading Acanthosis Nigricans Using a Smartphone and Color Analysis: A Novel Noninvasive Method to Screen for Impaired Glucose Tolerance and Type 2 Diabetes 利用智能手机和色彩分析对黑棘皮病进行分级：筛查糖耐量受损和 2 型糖尿病的新型无创方法

Diabetes Spectrum Pub Date : 2024-02-05 DOI: 10.2337/ds23-0042

A. Dhanoo, Sterling Ramroach, Felicia Hill-Briggs, Brian N. Cockburn

{"title":"Grading Acanthosis Nigricans Using a Smartphone and Color Analysis: A Novel Noninvasive Method to Screen for Impaired Glucose Tolerance and Type 2 Diabetes","authors":"A. Dhanoo, Sterling Ramroach, Felicia Hill-Briggs, Brian N. Cockburn","doi":"10.2337/ds23-0042","DOIUrl":"https://doi.org/10.2337/ds23-0042","url":null,"abstract":"\u0000 \u0000 The objective of this study was to develop ANcam, a novel method for identifying acanthosis nigricans (AN) using a smartphone camera and computer-aided color analysis for noninvasive screening of people with impaired glucose tolerance (IGT).\u0000 \u0000 \u0000 \u0000 Adult and juvenile participants with or without diagnosed type 2 diabetes were recruited in Trinidad and Tobago. After obtaining informed consent, participants’ history, demographics, anthropometrics, and A1C were collected and recorded. Three subject-matter experts independently graded pictures of the posterior neck and upper back using the ANcam smartphone application and Burke methods. A correlation matrix investigated 25 color channels for association with hyperpigmentation, and the diagnostic thresholds were determined with a receiver operating characteristic curve analysis.\u0000 \u0000 \u0000 \u0000 For the 227 participants with captured images and A1C values, the cyan/magenta/yellow/black (CMYK) model color channel CMYK_K was best correlated with IGT at an A1C cut-off of 5.7% [39 mmol/mol] (R = 0.45, P <0.001). With high predictive accuracy (area under the curve = 0.854), the cut-off of 7.67 CMYK_K units was chosen, with a sensitivity of 81.1% and a specificity of 70.3%. ANcam had low interrater variance (F = 1.99, P = 0.137) compared with Burke grading (F = 105.71, P <0.001). ANcam detected hyperpigmentation on the neck at double the self-reported frequency. Elevated BMI was 2.9 (95% CI 1.9–4.3) times more likely, elevated blood pressure was 1.7 (95% CI 1.2–2.4) times more likely, and greater waist-to-hip ratio was 2.3 (95% CI 1.4–3.6) times more likely with AN present.\u0000 \u0000 \u0000 \u0000 ANcam offers a sensitive, reproducible, and user-friendly IGT screening tool to any smartphone user that performs well with most skin tones and lighting conditions.\u0000","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"213 2","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139862520","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Grading Acanthosis Nigricans Using a Smartphone and Color Analysis: A Novel Noninvasive Method to Screen for Impaired Glucose Tolerance and Type 2 Diabetes 利用智能手机和色彩分析对黑棘皮病进行分级：筛查糖耐量受损和 2 型糖尿病的新型无创方法

Diabetes Spectrum Pub Date : 2024-02-05 DOI: 10.2337/ds23-0042

A. Dhanoo, Sterling Ramroach, Felicia Hill-Briggs, Brian N. Cockburn

{"title":"Grading Acanthosis Nigricans Using a Smartphone and Color Analysis: A Novel Noninvasive Method to Screen for Impaired Glucose Tolerance and Type 2 Diabetes","authors":"A. Dhanoo, Sterling Ramroach, Felicia Hill-Briggs, Brian N. Cockburn","doi":"10.2337/ds23-0042","DOIUrl":"https://doi.org/10.2337/ds23-0042","url":null,"abstract":"\u0000 \u0000 The objective of this study was to develop ANcam, a novel method for identifying acanthosis nigricans (AN) using a smartphone camera and computer-aided color analysis for noninvasive screening of people with impaired glucose tolerance (IGT).\u0000 \u0000 \u0000 \u0000 Adult and juvenile participants with or without diagnosed type 2 diabetes were recruited in Trinidad and Tobago. After obtaining informed consent, participants’ history, demographics, anthropometrics, and A1C were collected and recorded. Three subject-matter experts independently graded pictures of the posterior neck and upper back using the ANcam smartphone application and Burke methods. A correlation matrix investigated 25 color channels for association with hyperpigmentation, and the diagnostic thresholds were determined with a receiver operating characteristic curve analysis.\u0000 \u0000 \u0000 \u0000 For the 227 participants with captured images and A1C values, the cyan/magenta/yellow/black (CMYK) model color channel CMYK_K was best correlated with IGT at an A1C cut-off of 5.7% [39 mmol/mol] (R = 0.45, P <0.001). With high predictive accuracy (area under the curve = 0.854), the cut-off of 7.67 CMYK_K units was chosen, with a sensitivity of 81.1% and a specificity of 70.3%. ANcam had low interrater variance (F = 1.99, P = 0.137) compared with Burke grading (F = 105.71, P <0.001). ANcam detected hyperpigmentation on the neck at double the self-reported frequency. Elevated BMI was 2.9 (95% CI 1.9–4.3) times more likely, elevated blood pressure was 1.7 (95% CI 1.2–2.4) times more likely, and greater waist-to-hip ratio was 2.3 (95% CI 1.4–3.6) times more likely with AN present.\u0000 \u0000 \u0000 \u0000 ANcam offers a sensitive, reproducible, and user-friendly IGT screening tool to any smartphone user that performs well with most skin tones and lighting conditions.\u0000","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"5 9","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139802660","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals 非危重病人每日一次与每日两次胰岛素格拉贡剂量的回顾性分析

Diabetes Spectrum Pub Date : 2024-02-05 DOI: 10.2337/ds23-0029

Deasiah Hogue, Jennifer Clements, Adrienne Wright

{"title":"Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals","authors":"Deasiah Hogue, Jennifer Clements, Adrienne Wright","doi":"10.2337/ds23-0029","DOIUrl":"https://doi.org/10.2337/ds23-0029","url":null,"abstract":"\u0000 \u0000 Insulin is the treatment of choice for diabetes care in the hospital. There is some debate regarding the efficacy and safety of once-daily versus twice-daily insulin glargine in the hospital, particularly in the critically ill population.\u0000 \u0000 \u0000 \u0000 The purpose of this pilot study was to evaluate the efficacy and safety of insulin glargine administered as a once-daily versus twice-daily regimen in the noncritically ill population.\u0000 \u0000 \u0000 \u0000 A retrospective chart review was conducted from 1 June 2020 to 31 May 2021. Inclusion criteria were age ≥18 years and on a regimen of either once-daily or twice-daily insulin glargine for ≥72 hours during the specified time frame. The primary end point was a comparison of the number of days with all blood glucose measurements within the range of 70–180 mg/dL throughout a 24-hour period. Secondary end points included the number of hyperglycemic (>180 mg/dL) and hypoglycemic (<70 mg/dL) events that occurred in each study group.\u0000 \u0000 \u0000 \u0000 Group 1 included 101 individuals who received once-daily dosing, and group 2 included 103 individuals who received twice-daily dosing. Baseline characteristics were similar between the groups except for a higher BMI at admission (P = 0.01) and a higher pre-admission A1C (P = 0.02) in group 2. No differences were found for the primary end point (P = 0.5) or for hypoglycemic (P = 0.6) or hyperglycemic (P = 0.7) events.\u0000 \u0000 \u0000 \u0000 There were no significant differences in efficacy or safety between once-daily and twice-daily insulin glargine in the noncritically ill population. A larger prospective study could confirm these results.\u0000","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"11 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139803278","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals 非危重病人每日一次与每日两次胰岛素格拉贡剂量的回顾性分析

Diabetes Spectrum Pub Date : 2024-02-05 DOI: 10.2337/ds23-0029

Deasiah Hogue, Jennifer Clements, Adrienne Wright

{"title":"Retrospective Analysis of Once-Daily Versus Twice-Daily Insulin Glargine Dosing in Noncritically Ill Individuals","authors":"Deasiah Hogue, Jennifer Clements, Adrienne Wright","doi":"10.2337/ds23-0029","DOIUrl":"https://doi.org/10.2337/ds23-0029","url":null,"abstract":"\u0000 \u0000 Insulin is the treatment of choice for diabetes care in the hospital. There is some debate regarding the efficacy and safety of once-daily versus twice-daily insulin glargine in the hospital, particularly in the critically ill population.\u0000 \u0000 \u0000 \u0000 The purpose of this pilot study was to evaluate the efficacy and safety of insulin glargine administered as a once-daily versus twice-daily regimen in the noncritically ill population.\u0000 \u0000 \u0000 \u0000 A retrospective chart review was conducted from 1 June 2020 to 31 May 2021. Inclusion criteria were age ≥18 years and on a regimen of either once-daily or twice-daily insulin glargine for ≥72 hours during the specified time frame. The primary end point was a comparison of the number of days with all blood glucose measurements within the range of 70–180 mg/dL throughout a 24-hour period. Secondary end points included the number of hyperglycemic (>180 mg/dL) and hypoglycemic (<70 mg/dL) events that occurred in each study group.\u0000 \u0000 \u0000 \u0000 Group 1 included 101 individuals who received once-daily dosing, and group 2 included 103 individuals who received twice-daily dosing. Baseline characteristics were similar between the groups except for a higher BMI at admission (P = 0.01) and a higher pre-admission A1C (P = 0.02) in group 2. No differences were found for the primary end point (P = 0.5) or for hypoglycemic (P = 0.6) or hyperglycemic (P = 0.7) events.\u0000 \u0000 \u0000 \u0000 There were no significant differences in efficacy or safety between once-daily and twice-daily insulin glargine in the noncritically ill population. A larger prospective study could confirm these results.\u0000","PeriodicalId":39737,"journal":{"name":"Diabetes Spectrum","volume":"76 5","pages":""},"PeriodicalIF":0.0,"publicationDate":"2024-02-05","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"139863355","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

About Kenneth Cusi: Guest Editor 关于肯尼斯-库西：客座编辑

Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/ds24-ge01

引用次数: 0

Practical Lifestyle Management of Nonalcoholic Fatty Liver Disease for Busy Clinicians 为忙碌的临床医生提供实用的非酒精性脂肪肝生活方式管理方法

Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0009

S. Zelber-Sagi, J. Bernadette Moore

引用次数: 3

Role of Insulin Resistance in the Development of Nonalcoholic Fatty Liver Disease in People With Type 2 Diabetes: From Bench to Patient Care 胰岛素抵抗在 2 型糖尿病患者非酒精性脂肪肝发展过程中的作用：从工作台到患者护理

Diabetes Spectrum Pub Date : 2024-02-01 DOI: 10.2337/dsi23-0013

Juan Patricio Nogueira, Kenneth Cusi

引用次数: 1